甘露藏药：增资扩股引入战略投资者项目竞争性谈判会议顺利举行

Core Viewpoint - The strategic investment in Xizang Ganlu Tibetan Medicine Co., Ltd. marks a significant step towards achieving the company's listing goals and aligns with the regional "Galsang Flower Action" plan [1][4]. Group 1: Strategic Investors - The strategic investors include a powerful lineup, such as the State-owned Enterprise Mixed Ownership Reform Fund, which is a national-level fund initiated by the State-owned Assets Supervision and Administration Commission [3]. - Other investors include Guangzhou Pharmaceutical Holdings, a Fortune Global 500 company focused on traditional Chinese medicine, and Chengdu Wufang Industrial Equity Investment Fund, which has a total scale exceeding 44 billion [3]. - Xizang Trust, a financial institution controlled by the Tibet Autonomous Region Finance Department, has established long-term partnerships with over 100 listed companies [3]. Group 2: Investment Purpose and Impact - The investment of approximately 174 million will leverage the strengths of strategic shareholders in capital, industry, channels, and management to enhance the company's core competitiveness [4]. - The company aims to expand its production capacity, improve its industrial chain, protect its brand, and enhance market expansion efforts [4]. - The focus is on domestic market development, particularly targeting major markets in Beijing, the Yangtze River Delta, and Southwest China, to establish a solid foundation for the national expansion of Tibetan medicine [5].